1 min read
Belite Bio Shares Fall 13% as FDA Sets New Tinlarebant Action Date
The FDA set May 12, 2027, as the new action date for tinlarebant’s application for Stargardt disease type 1.

Belite Bio (BLTE) shares fell about 13% Friday, Nov. 20, 2026, after the U.S. Food and Drug Administration (FDA) moved the review deadline for the company’s tinlarebant application back by three months.
The agency set May 12, 2027, as the new target action date for the application for tinlarebant for Stargardt disease type 1.